A Declaration from Members of the World’s Biotechnology Sector On Global Access to COVID Vaccines & Treatments and the Role of Intellectual Property

We, the undersigned CEOs of global biotechnology companies and associations have a social responsibility to work with other stakeholders to ensure that COVID vaccines and treatments get to the patients in the world who most need them.

Pragmatic IP solutions and strong collaborations will ensure faster global access to vaccines


IP waiver for COVID-19 vaccines is a misguided and ineffective response to a shared global challenge

2021_05_H_PR_Waiver of Intellectual Property Rights for COVID-19 Vaccines – EuropaBio’s Position

An EU IP Action Plan for strong industrial ecosystems

An EU IP Action Plan for strong industrial ecosystems

Export Manufacturing Waiver for Supplementary Protection Certificates: a red flag for investment in EU healthcare biotech

As the Association representing the European biotechnology industry, EuropaBio is fully committed to the development of a legislative environment which facilitates the creation of EU jobs and growth as well as new solutions to healthcare challenges.

SPC waiver risks downgrading the EU as a hub for Health Innovation

As an association that has manufacturers of both originator and biosimilar medicines as members, EuropaBio strongly doubts that the promises of today’s Commission proposal outweigh the risks of losing investment in new medicines.

From Patent to Patient – The importance of IP rewards and incentives

The system of IP rewards and incentives exists and works together to allow adequate time for the companies and investors to recoup their years of investment and fully realise clinical value before their inventions become part of the public domain and can be used by others.